The urgent and global need for democratized blood-based biomarker diagnostics in Alzheimer's disease
The Journal of Precision Medicine: Health and Disease · 2025
DOI: 10.1016/j.premed.2025.100002 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Precision Medicine: Health and Disease, 2025. Verfasst von Steven D. Quinn. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Society.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) represents one of the most pressing healthcare challenges of the 21st century. As a leading cause of dementia, AD impacts over 55 million people worldwide, with this number projected to exceed 139 million by 2050. The economic burden is staggering, with global costs estimated to reach over $15 trillion, placing immense strain on healthcare systems, patients and caregivers (Chen et al., 2024; Nandi et al., 2022). Despite significant recent progress in understanding the molecular pathology of AD, and in the development of emerging treatments (Mead & Fox, 2023; Sims et al., 2023), access to timely and widespread diagnosis remains a formidable challenge.
Förderung
- Alzheimer's Society
Zitieren
APA
Quinn, S. D. (2025). The urgent and global need for democratized blood-based biomarker diagnostics in Alzheimer's disease. The Journal of Precision Medicine: Health and Disease. https://doi.org/10.1016/j.premed.2025.100002
Vancouver
Quinn SD. The urgent and global need for democratized blood-based biomarker diagnostics in Alzheimer's disease. The Journal of Precision Medicine: Health and Disease. 2025. doi:10.1016/j.premed.2025.100002
BibTeX
@article{Quinn2025,
author = {Quinn, Steven D.},
title = {The urgent and global need for democratized blood-based biomarker diagnostics in Alzheimer's disease},
journal = {The Journal of Precision Medicine: Health and Disease},
year = {2025},
doi = {10.1016/j.premed.2025.100002}
}
EUVIMED